Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 54
Filtrar
1.
Eur J Gynaecol Oncol ; 35(4): 421-4, 2014.
Artigo em Inglês | MEDLINE | ID: mdl-25118484

RESUMO

PURPOSE: Ovarian cancer is the fourth cause of death from cancer in women worldwide and the majority of its diagnoses is made in an advanced stage of the disease. Several sonographic scoring systems have been created for a better preoperative discrimination between benign and malignant pelvic masses. The aim of this study was to evaluate the performances of the Risk of the Malignancy Index 3 (RMI 3) and the Pelvic Masses Score (PMS). MATERIALS AND METHODS: This retrospective study was performed in 55 women admitted to the department of Obstetrics and Gynecology of University of Udine for surgical exploration of pelvic masses between 2009 and 2012. Sensitivity, specificity, positive predictive value (PPV) and negative predictive value (NPV) were calculated for both the scores. RESULTS: PMS showed a sensitivity of 100%, a specificity of 93.8%, a PPV of 70%, and a NPV of 100%, while RMI 3 yielded a sensitivity of 85%, a specificity of 91%, a PPV of 60%, and a NPV of 97.8%. CONCLUSION: The authors found that, in discriminating between benign and malignant pelvic disease, the PMS method was more reliable than RMI3. PMS is a simple scoring system which can be used in clinical practice.


Assuntos
Carcinoma Endometrioide/diagnóstico por imagem , Cistadenocarcinoma Seroso/diagnóstico por imagem , Cistadenoma Mucinoso/diagnóstico por imagem , Cistadenoma Seroso/diagnóstico por imagem , Cistos Ovarianos/diagnóstico por imagem , Neoplasias Ovarianas/diagnóstico por imagem , Teratoma/diagnóstico por imagem , Adulto , Idoso , Idoso de 80 Anos ou mais , Antígeno Ca-125/sangue , Carcinoma Endometrioide/sangue , Carcinoma Endometrioide/patologia , Cistadenocarcinoma Seroso/sangue , Cistadenocarcinoma Seroso/patologia , Cistadenoma Mucinoso/sangue , Cistadenoma Mucinoso/patologia , Cistadenoma Seroso/sangue , Cistadenoma Seroso/patologia , Feminino , Humanos , Proteínas de Membrana/sangue , Pessoa de Meia-Idade , Cistos Ovarianos/sangue , Cistos Ovarianos/patologia , Neoplasias Ovarianas/sangue , Neoplasias Ovarianas/patologia , Valor Preditivo dos Testes , Curva ROC , Estudos Retrospectivos , Medição de Risco , Sensibilidade e Especificidade , Teratoma/sangue , Teratoma/patologia , Ultrassonografia , Adulto Jovem
2.
Minerva Ginecol ; 66(5): 443-7, 2014 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-24743523

RESUMO

AIM: The aim of this paper was to identify maternal/pregnancy characteristics, first trimester ultrasound parameters and biochemical indices which are significant independent predictors of large-for-gestational age (LGA) neonates. METHODS: An Observational cross-sectional study was conducted at the Fetal Medicine Unit, Department of Obstetrics and Gynecology of the University of Udine (Italy). Seventy-two singleton pregnancies presenting for screening for chromosomal abnormalities by nuchal translucency and maternal serum biochemistry at 11-14 weeks. Linear regression was applied to develop first trimester prediction models for LGA. RESULTS: Maternal height, parity, smoking, assisted conception and pregnancy-associated plasma protein-A were significant independent predictors of LGA. PAPP-A cut-off value expressed in MoM of 1.25 used for the study was chosen to obtain good sensitivity and specificity values. CONCLUSION: Prediction for birthweight deviations (LGA) is feasible using data available at the routine 11-14 weeks' examination.


Assuntos
Peso ao Nascer/fisiologia , Proteína Plasmática A Associada à Gravidez/análise , Ultrassonografia Pré-Natal/métodos , Adolescente , Adulto , Estudos Transversais , Estudos de Viabilidade , Feminino , Humanos , Recém-Nascido , Itália , Modelos Lineares , Medição da Translucência Nucal , Gravidez , Primeiro Trimestre da Gravidez , Sensibilidade e Especificidade , Adulto Jovem
3.
J Obstet Gynaecol ; 32(1): 58-61, 2012 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22185539

RESUMO

Benign breast disease (BBD) is very common among women in their fertile age, but its correlation with breast reproductive function remains unclear. Our study aimed to investigate the relation between BBD and breast-feeding. We collected data on 105 women with BBD and 98 controls, focusing on their reproductive history and breast-feeding. We analysed data by R (version 2.12.1) considering p < 0.05 as significant. The results showed that fibroadenoma represented the most frequent BBD (55%), followed by fibrocystic changes (19%), intraductal papilloma (6%) and inflammatory breast disorders (5%). The mean age was 31.5 years (± 6.1), BMI 21.2 kg/m² (± 3.4) and age at menarche 13.0 years (± 1.5). Duration of breast-feeding was not significantly different between controls and BBD types (p = NS). Selecting women with fibroadenoma breast-feeding duration directly correlated with the number of benign lesions (p < 0.05), which remains significant also by multivariate analysis. It was concluded that there seemed to be no difference in breast-feeding among BBDs types, but lactation may influence the number of fibroadenomas. Moreover, prospective studies would better define the correlation between lactation and BBDs.


Assuntos
Aleitamento Materno/estatística & dados numéricos , Doença da Mama Fibrocística/epidemiologia , Lactação , Adulto , Neoplasias da Mama/epidemiologia , Estudos de Casos e Controles , Feminino , Humanos , Itália/epidemiologia , Mastite/epidemiologia , Papiloma Intraductal/epidemiologia , Gravidez
4.
Clin Exp Obstet Gynecol ; 39(4): 504-8, 2012.
Artigo em Inglês | MEDLINE | ID: mdl-23444754

RESUMO

PURPOSE OF INVESTIGATION: The aim of this study was to evaluate the ovarian function in women who received or not gonadotropin-releasing hormone (GnRH) analogue co-treatment compared to the control group that did not receive it. MATERIALS AND METHODS: This study analyzed 124 patients affected by hematological diseases between 1998 and 2007. The data were analyzed using R (v 2.9.1). RESULTS: In the women treated with GnRH analogue, the authors found 33% post-treatment secondary amenorrhea and 6% had a pregnancy post-treatment, while in the other group the prevalence were respectively 49% and 4% (p n.s.). Moreover, in multivariate analysis the authors found bone marrow transplantation to be a risk factor for secondary amenorrhea, while the association of chemotherapy with radiotherapy was a protective factor (p < 0.05). Finally, none of the considered factors were predictive of pregnancy achievement post-treatment. CONCLUSIONS: The authors found no statistical evidence to support that Gn-RH analogue treatment preserves ovarian follicular reserve during hematologic cancer treatment, but more evidence must be obtained.


Assuntos
Antineoplásicos/efeitos adversos , Hormônio Liberador de Gonadotropina/análogos & derivados , Neoplasias Hematológicas/tratamento farmacológico , Ovário/efeitos dos fármacos , Insuficiência Ovariana Primária/prevenção & controle , Adulto , Amenorreia/induzido quimicamente , Quimioterapia Combinada , Feminino , Fertilidade , Doença de Hodgkin/tratamento farmacológico , Humanos , Leucemia Mieloide Aguda/tratamento farmacológico , Linfoma não Hodgkin/tratamento farmacológico , Análise Multivariada , Ovário/fisiologia , Gravidez , Insuficiência Ovariana Primária/induzido quimicamente , Estudos Prospectivos , Sobreviventes , Adulto Jovem
5.
Minerva Ginecol ; 63(2): 181-7, 2011 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-21508906

RESUMO

AIM: Over genetic and obsteteric factors, also autoimmunity may be involved in female chronic pelvic pain (CPP) pathogenesis. Our study aims to determinate the prevalence of CPP after one year from delivery, and to investigate the possible influence on CPP of concomitant autoimmune conditions. Methods. We selected a cohort of caucasian primipara and secondipara who delivered in our clinic in 2006. We collected personal, clinical and obstetric data, and asked them about pelviperineal painful symptoms. Results. Mean maternal age is 35.52 years (±4.70), 27.65% of women delivered by cesarean section, 61.04% spontaneously and 11.32% by operative assistance, with partoanalgesia in 10.39% of cases, episiotomy in 41.19%, vaginoperineal tears in respectively 14.10% I degree, 11.13% II degree and 0.93% III-IV degree; 43.60% of women have ever undergone abdominopelvic surgery, 32.84% by laparotomy-laparoscopy, 7.05% by hysteroscopy, 5.01% limited to perineum. Chronic autoimmune diseases affect 78.48% of women, allergies 7.79%, rheumatic pathologies 1.3%, autoimmune endocrinopathies 71.8%; 26.53% of women report pelviperineal painful symptoms, being already present in 2.23% of cases, 12.43% generalised pelvic pain, 4.27% bladder pain, 2.60% vulvodynia, 17. 07% dyspareunia. By monovariate analysis CPP results influenced by III-IV degree vaginoperineal tears, operative assistance, preexisting CPP, previous and actual urinary incontinence, previous abdominopelvic surgical interventions and chronic rheumatic pathologies. Furthermore, rheumatic disease, operative assistance and previous CPP are predictive factors for CPP in the postpartum (AUC=58.10%). Conclusion. Delivery may highlight CPP symptoms in predisposed women affected by chronic autoimmune pathologies.


Assuntos
Doenças Autoimunes/complicações , Dor Pélvica/imunologia , Adulto , Doença Crônica , Feminino , Humanos , Paridade , Gravidez , Fatores de Risco , Fatores de Tempo
6.
Minerva Ginecol ; 62(2): 97-103, 2010 Apr.
Artigo em Italiano | MEDLINE | ID: mdl-20502422

RESUMO

AIM: The aim of this study was to suggest a possible obstetric management of patients with intrahepatic cholestasis of pregnancy (ICP). METHODS: We performed a retrospective analysis enrolling 44 women with ICP deliveries at our Obstetrics and Gynaecology clinic of the University of Udine between January 2005 and July 2008. Data on patient age, body mass index, weight, gestational age, parity, symptoms, comorbidity, value of liver test, APGAR score and fetal weight were prospectively recorded in a computed database and clinical folder. RESULTS: The intensification of maternal and fetal surveillance in patients with ICP (liver function tests, ultrasound and cardiotocography), can significantly reduce perinatal mortality (no case of stillbirth in ours study) but, inevitably, increases the cesarean delivery rate (65.1%), the induction of labor rate (38.4%) and the preterm delivery rate (58.13 %, median gestational age 35 sg+/-1.46). CONCLUSION: Obstetric management of ICP consist of weighing the risk of premature delivery against the risk of sudden death in utero. To date, no ideal method of fetal surveillance has been determined for ICP; the intrauterine deaths are thought to occur suddenly and fetal cardiac monitoring cannot forecast an acute event. Nevertheless, we think that a management strategy, inclusive of induction of labor at 37 weeks, can reduces the risk of fetal death. In most severe cases, no responsive to ursodeoxycholic acid and S-adenosylmethionine treatment, delivery has been initiated even before the 37 weeks, as soon as lung maturity has been established.


Assuntos
Colestase Intra-Hepática/diagnóstico , Complicações na Gravidez/diagnóstico , Complicações na Gravidez/terapia , Adulto , Colestase Intra-Hepática/terapia , Feminino , Humanos , Gravidez , Estudos Retrospectivos
7.
Minerva Ginecol ; 61(2): 81-7, 2009 Apr.
Artigo em Italiano | MEDLINE | ID: mdl-19255555

RESUMO

AIM: Knowledge of human papilloma virus (HPV) infection and related genital lesions and vaccine is related to the success of the vaccination program. Authors have assessed knowledge, attitudes and beliefs on HPV and vaccination in a sample of women, in order to optimize any educational interventions. METHODS: This study enrolled 212 consecutive women with no history of HPV-related genital lesions by means of an anonymous questionnaire. The questionnaire included 21 questions (19 with a multiple choice and 2 with open answers) to check awareness of HPV infection and related lesions, HPV transmission, vaccine and vaccination program expectations, sexual/precautionary behaviours after vaccination and the need felt for more information. RESULTS: Forty-two percent of women in the study population know about HPV-related genital lesions, and 43% are aware of the right way of transmission; 75% have learned about the vaccine. In this last group 28% know that the vaccine efficiency is mainly limited to the HPV types included in the vaccine, 19.8% know that one of the vaccines can also prevent genital condylomata and 88% have heard about this vaccination program. CONCLUSIONS: There is still a lack of information or access to information about HPV and more needs to be done to raise awareness of HPV vaccination. A percentage of 74.4 of women wish to receive more information and thinks that schools and family planning clinics should play a central role in teenagers' health education. There is a need to further train healthcare workers involved in the vaccination program in order to optimize their counselling to teenagers and parents.


Assuntos
Conhecimentos, Atitudes e Prática em Saúde , Papillomaviridae/imunologia , Infecções por Papillomavirus/prevenção & controle , Vacinas contra Papillomavirus/uso terapêutico , Vacinação/métodos , Adolescente , Adulto , Condiloma Acuminado/prevenção & controle , Feminino , Humanos , Itália/epidemiologia , Masculino , Pessoa de Meia-Idade , Infecções por Papillomavirus/epidemiologia , Infecções por Papillomavirus/transmissão , Estudos Retrospectivos , Tamanho da Amostra , Comportamento Sexual , Inquéritos e Questionários , Neoplasias do Colo do Útero/prevenção & controle , Adulto Jovem
8.
Minerva Ginecol ; 60(3): 231-8, 2008 Jun.
Artigo em Italiano | MEDLINE | ID: mdl-18547985

RESUMO

AIM: This prospective study was performed to evaluate perinatal outcome and maternal risk factors in pregnancies complicated by fetal intrauterine growth restriction (IUGR). METHODS: A total of 3 537 women pregnant with a singleton gestation were enrolled in the study: 219 of these pregnancies were complicated by fetal growth restriction (6.2%). Statistical analysis was performed using Wilcoxon test, Kruskall-Wallis test, c2 analysis of variance and ANOVA test. Statistical significance was set at P-value <0.05. Correlations were calculated by Spearman's coefficient. RESULTS: Ethnic group, physical demanding work, maternal smoking, alcohol abuse do not seem to be associated with lower birth weight and worse Apgar score. Sonographic assessment of fetal weight obtained by Hadlock's formula underestimate real newborn's weight. The difference between estimate weight and real weight is statistically significant. Women with intrauterine growth restriction underwent caesarean sections more often than women with appropriate fetal growth selected as controls (P<0.05). CONCLUSION: In conclusion, the obstetrician must recognize and accurately diagnose inadequate fetal growth and attempt to determine its cause (especially placental factors) in order to reduce fetal and maternal risks and establish the appropriate clinical management, timing and mode of delivery. If the growth-restricted fetus is identified and appropriate management instituted, perinatal mortality can be reduced.


Assuntos
Retardo do Crescimento Fetal/mortalidade , Retardo do Crescimento Fetal/fisiopatologia , Mortalidade Infantil , Índice de Apgar , Feminino , Humanos , Recém-Nascido , Itália/epidemiologia , Gravidez , Complicações na Gravidez/mortalidade , Resultado da Gravidez , Estudos Prospectivos
9.
Minerva Ginecol ; 60(2): 97-104, 2008 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-18487959

RESUMO

AIM: The aim of this observational study is the identification of women at high risk of osteoporosis by using the phalangeal quantitative ultrasound (QUS) value for osteoporosis screening. METHODS: The study population is composed of 1 152 women between 35 and 79 years old, both premenopausal and postmenopausal. Each woman underwent a questionnaire and phalangeal QUS. One hundred and forty-eight women also underwent dual energy X-ray absorptiometry (DEXA). Osteopenia and osteoporosis, as determined using the amplitude dependent speed of sound (AD-SoS) T-score, identified women at a high risk of fracture. Data were stored and analyzed using SPSS (Statistical Package for Social Science) for Windows. RESULTS: AD-SoS is significantly higher in premenopausal women than in postmenopausal women without history of hormone replacement therapy (HRT) (P<0.001), if they are over 50 years old. In women 50-59 years old, AD-SoS is significantly higher in premenopausal women than in postmenopausal women with or without HRT history (P<0.001). In postmenopausal women, discriminant analysis found that HRT and years of HRT are the only significant protective factors (P<0.001). In premenopausal and postmenopausal women with no history of HRT use, discriminant analysis demonstrated that early menopause and a family history of osteoporosis are the only significant risk factors (P<0.001). CONCLUSION: Early menopause and a family history of osteoporosis seem to be the greatest risk factors, while HRT seems to be a protective factor. The QUS technique, with DEXA as a secondary test, can be a screening test for the identification of postmenopausal women with a high risk of fracture.


Assuntos
Absorciometria de Fóton , Programas de Rastreamento/métodos , Osteoporose/diagnóstico , Osteoporose/epidemiologia , Adulto , Idoso , Área Programática de Saúde , Feminino , Humanos , Itália/epidemiologia , Pessoa de Meia-Idade , Osteoporose/diagnóstico por imagem , Fatores de Risco , Ultrassonografia
10.
Cancer Invest ; 24(6): 611-4, 2006 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-16982466

RESUMO

Carriers of BRCA2 germline mutation have a significantly increased lifetime risk of breast and ovarian cancer compared to non carriers. Several other carcinomas seem to be associated with BRCA2 mutations: pancreas, prostate, larynx, gallbladder, bile duct cancer, and malignant melanoma. We described a case of a 67-year-old BRCA2 mutation carrier of Caucasian, non-Jewish, ethnic origin who successively developed 4 primary malignancies in 30 months: breast ductal carcinoma, chronic lymphatic leukemia, ovarian serous papillary carcinoma, and endocervical adenocarcinoma. This is the first case of 4 primary malignancies in a BRCA mutation carrier, also occurred in such a short observation period. Chronic lymphatic leukemia and endocervical adenocarcinoma have not been yet associated to BRCA2 germline mutation.


Assuntos
Proteína BRCA2/genética , Neoplasias da Mama/genética , Mutação em Linhagem Germinativa , Leucemia Linfocítica Crônica de Células B/genética , Neoplasias Primárias Múltiplas/genética , Neoplasias Ovarianas/genética , Neoplasias do Colo do Útero/genética , Adenocarcinoma/genética , Adenocarcinoma/patologia , Adenocarcinoma/terapia , Adulto , Idoso , Neoplasias da Mama/patologia , Neoplasias da Mama/terapia , Carcinoma Ductal de Mama/genética , Carcinoma Ductal de Mama/patologia , Carcinoma Ductal de Mama/terapia , Cistadenocarcinoma Papilar/genética , Cistadenocarcinoma Papilar/patologia , Cistadenocarcinoma Papilar/terapia , Cistadenocarcinoma Seroso/genética , Cistadenocarcinoma Seroso/patologia , Cistadenocarcinoma Seroso/terapia , Feminino , Predisposição Genética para Doença , Humanos , Leucemia Linfocítica Crônica de Células B/patologia , Leucemia Linfocítica Crônica de Células B/terapia , Masculino , Pessoa de Meia-Idade , Neoplasias Primárias Múltiplas/patologia , Neoplasias Primárias Múltiplas/terapia , Neoplasias Ovarianas/patologia , Neoplasias Ovarianas/terapia , Linhagem , Neoplasias do Colo do Útero/patologia , Neoplasias do Colo do Útero/terapia
12.
Minerva Ginecol ; 58(2): 171-5, 2006 Apr.
Artigo em Italiano | MEDLINE | ID: mdl-16582871

RESUMO

Genetic investigation of BRCA1 and BRCA2 germline mutations is, nowadays, a diagnostic procedure with practical clinical applications. The role of this genes in DNA repair and stability and in cancer development is now well recognised. Most involved are breast and ovarian cancers, but, less frequently, other gynecological cancers like cervical, corpus uteri and Fallopian tubes cancers and also other non gynecological malignancies. We report the case of a 67-year-old patient with strong familiarity for breast cancer, with a BRCA2 germline mutation, who developed in 30 months 4 primary malignancies: in chronological order, breast cancer, chronic lymphatic leukemia, and synchronous ovarian and endocervical adenocarcinoma. A better knowledge of the biological and clinical behaviour of BRCA related cancers is of strategical importance in the management of patients with strong familiar neoplastic history or with genetic test positivity. An adequate counselling can help in the management of these cancers in the prevention and early diagnosis taking also into consideration the possibility of a prophylactic surgery.


Assuntos
Adenocarcinoma/genética , Proteína BRCA1/genética , Proteína BRCA2/genética , Neoplasias da Mama/genética , Leucemia Linfocítica Crônica de Células B/genética , Neoplasias Primárias Múltiplas/genética , Neoplasias Ovarianas/genética , Neoplasias do Colo do Útero/genética , Idoso , Feminino , Humanos , Mutação , Linhagem
13.
Maturitas ; 53(1): 59-64, 2006 Jan 10.
Artigo em Inglês | MEDLINE | ID: mdl-15939560

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effects of different types of hormone replacement therapy (HRT) on mammographic density. MATERIALS AND METHODS: In a prospective 1-year study, 103 postmenopausal women were randomized to receive tibolone 2.5 mg/die, continuous conjugated equine estrogens 0.625 mg/die plus medroxyprogesterone acetate (MPA) 5mg/die or placebo. Mammograms were performed at baseline and after 12 months of treatment. Mammographic density was quantified according to the Wolfe classification. RESULTS: After 12 months of HRT 16 of the 35 patients (45.1%) receiving continuous combined hormonal therapy showed an increase of breast density change in the Wolfe classification. After treatment with tibolone, an up grading in breast density, according to Wolfe's classification, was found in 2 of the 43 patients (2.3%). No changes were recorded in the 25 patients of the control group. The difference between the group treated with continuous combined hormonal therapy and the control group was highly significant (p<0.001). The difference in breast density between patients in treatment with tibolone and the control group was not statistically significant (p=0.34). DISCUSSION: Continuous combination HRT may be more commonly associated with an increase of mammography density than tibolone treatment.


Assuntos
Mama/efeitos dos fármacos , Moduladores de Receptor Estrogênico/farmacologia , Terapia de Reposição de Estrogênios/métodos , Estrogênios/farmacologia , Mamografia , Acetato de Medroxiprogesterona/farmacologia , Norpregnenos/farmacologia , Mama/anatomia & histologia , Neoplasias da Mama/diagnóstico por imagem , Moduladores de Receptor Estrogênico/administração & dosagem , Estrogênios/administração & dosagem , Estrogênios Conjugados (USP)/administração & dosagem , Estrogênios Conjugados (USP)/farmacologia , Feminino , Seguimentos , Humanos , Acetato de Medroxiprogesterona/administração & dosagem , Pessoa de Meia-Idade , Norpregnenos/administração & dosagem , Pós-Menopausa , Estudos Prospectivos , Método Simples-Cego , Resultado do Tratamento
14.
Maturitas ; 52(3-4): 181-9, 2005.
Artigo em Inglês | MEDLINE | ID: mdl-16257609

RESUMO

OBJECTIVE: To obtain data on correlates of climacteric symptoms in women around menopause attending menopause clinics in Italy. METHODS: Since 1997 a large cross sectional study has been conducted on the characteristics of women around menopause attending a network of first level menopause outpatient's clinics in Italy. A total of 66,501 (mean age 54.4 years) women are considered in the present paper. RESULTS: The odds ratios of moderate and severe hot flashes/night sweats were lower in more educated women and (for severe symptoms only) in women reporting regular physical activity. Depression, difficulty to sleep, forgetfulness and irritability tended to be less frequent in more educated women and (depression only) in women reporting regular physical activity. Parous women reported more frequently these symptoms. CONCLUSIONS: This large study confirms in Southern European population that low education, body mass index and low physical activity are associated with climacteric symptoms. Parous women are at greater risk of psychological symptoms.


Assuntos
Instituições de Assistência Ambulatorial/estatística & dados numéricos , Climatério/fisiologia , Menopausa/fisiologia , Adulto , Fatores Etários , Idoso , Índice de Massa Corporal , Climatério/psicologia , Estudos Transversais , Depressão/epidemiologia , Dieta , Escolaridade , Feminino , Cefaleia/epidemiologia , Fogachos/epidemiologia , Humanos , Itália/epidemiologia , Modelos Logísticos , Estado Civil , Menopausa/psicologia , Pessoa de Meia-Idade , História Reprodutiva , Fumar
15.
Minerva Ginecol ; 57(5): 545-50, 2005 Oct.
Artigo em Italiano | MEDLINE | ID: mdl-16205599

RESUMO

AIM: Premature ovarian failure (POF) can be considered a consequence of chemotherapy performed in patients affected by oncohematological disease. The aim of this study was to evaluate the administration of GnRh analogs (aGnRh) to prevent gonadal toxicity associated with cancer treatment. METHODS: From April 1996 to May 2002 a total of 49 fertile women affected by oncohematological diseases (Hodgkin's lymphoma, non-Hodgkin's lymphoma, acute leukemia) and treated with chemotherapy were evaluated. Ovarian function was studied through a 40.7 month observation period, after chemotherapy, in 3 different groups: women treated with aGnRh, oral contraceptives treatment and no preventive-treatment. The differences in these groups as to menstrual cycle, blood ovarian hormones, age at diagnosis, type and dosage of chemotherapy administered were evaluated. Statistical analysis was performed by chi2 test with Yates correction and Fisher test. RESULTS: All patients treated with aGnRh and chemotherapy achieved a good ovarian function. A normal ovarian function was also obtained in 75% of patients treated with oral contraceptives and only in 59.3% of women with no preventive treatment. Significant difference was found comparing aGnRh group with no preventive-treatment group (P<0.05). No significant differences were found between other groups. CONCLUSIONS: Use of GnRh analogs administered before beginning chemotherapy prevents from gonadal damage in all cases observed. Higher chemotherapy toxicity and older age at diagnosis time decrease ovarian function.


Assuntos
Antineoplásicos/efeitos adversos , Insuficiência Ovariana Primária/induzido quimicamente , Insuficiência Ovariana Primária/prevenção & controle , Adolescente , Adulto , Antineoplásicos/uso terapêutico , Antineoplásicos Hormonais/uso terapêutico , Anticoncepcionais Orais/uso terapêutico , Feminino , Hormônio Liberador de Gonadotropina/análogos & derivados , Neoplasias Hematológicas/tratamento farmacológico , Humanos , Estudos Longitudinais , Pessoa de Meia-Idade , Estudos Prospectivos , Pamoato de Triptorrelina/uso terapêutico
17.
Minerva Ginecol ; 56(5): 385-90, 2004 Oct.
Artigo em Italiano | MEDLINE | ID: mdl-15531855

RESUMO

AIM: Pre-eclampsia is one of the major causes of maternal and fetal morbidity and mortality. The aim of this study was to evaluate the clinical usefulness of screening of genetic thrombophilic mutations and uterine artery Doppler flow velocimetry at 24 weeks of gestation in the prediction of pre-eclampsia in low risk pregnant women. METHODS: We performed the genetic analysis for Leiden mutation of factor V gene (FV), G20210A mutation of the prothrombin gene (PT) and C677T polymorphism of the methylenetetrahydrofolate reductase (MTHFR) gene in 103 women that had already attended routine ultrasonography scanner at 24 weeks at our Department. RESULTS: The frequency of heterozygous carriers of the Leiden FV was 17.4% in women with pre-eclampsia and abnormal artery Doppler flow velocimetry compared with 3.12% in patients with normal pregnancies. This difference was statistically significant (P<0.05). The frequency of mutation G20210A of PT gene was 1.5% vs 4.3% between women with normal pregnancies and with pre-eclampsia. This difference is not statistically significant. The frequency of homozygous patients for the C677T mutation of MTHFR gene among patients with pre-eclampsia was 21.7% and in the control group was 10.3%, but this difference is not statistically significant. No thrombophilic genes variants were found in women with pre-eclampsia and normal uterine artery Doppler flow velocimetry. CONCLUSION: We demonstrated the important association between FV Leiden mutation, abnormal uterine artery Doppler flow velocimetry at 24 weeks and pre-eclampsia in our low-risk population.


Assuntos
Fator V/genética , Programas de Rastreamento , Metilenotetra-Hidrofolato Redutase (NADPH2)/genética , Mutação , Pré-Eclâmpsia/diagnóstico por imagem , Pré-Eclâmpsia/genética , Protrombina/genética , Útero/irrigação sanguínea , Adulto , Biomarcadores/metabolismo , Estudos de Casos e Controles , Feminino , Humanos , Programas de Rastreamento/métodos , Metilenotetra-Hidrofolato Redutase (NADPH2)/sangue , Reação em Cadeia da Polimerase , Pré-Eclâmpsia/sangue , Gravidez , Segundo Trimestre da Gravidez , Fluxo Pulsátil , Estudos Retrospectivos , Fatores de Risco , Ultrassonografia Doppler/métodos , Útero/diagnóstico por imagem
18.
Int J Gynaecol Obstet ; 81(3): 293-7, 2003 Jun.
Artigo em Inglês | MEDLINE | ID: mdl-12767572

RESUMO

OBJECTIVES: To investigate the effects of transdermal estrogen replacement therapy (ERT) on plasma homocysteine levels in postmenopausal women who underwent total hysterectomy with bilateral oophorectomy. METHODS: In two-phase open longitudinal prospective study we compared 28 premenopausal women and 35 healthy postmenopausal patients to evaluate the effect of transdermal estrogen treatment (TTS 50 twice-weekly) on plasma homocysteine levels after 6 and 12 months of therapy. RESULTS: The study showed statistically relevant differences (P<0.05) in baseline plasma homocysteine concentration between the patients in premenopausal and in postmenopausal status. No difference in the plasma homocysteine levels was observed after 6 and 12 months of ERT on postmenopausal patients. CONCLUSIONS: Surgically postmenopausal women have higher plasma homocysteine concentrations than premenopausal women, but transdermal estrogen treatment for 12 months in postmenopausal women does not modify homocysteine levels.


Assuntos
Estradiol/administração & dosagem , Estradiol/farmacologia , Terapia de Reposição de Estrogênios , Homocisteína/sangue , Homocisteína/efeitos dos fármacos , Menopausa/metabolismo , Pré-Menopausa/metabolismo , Administração Cutânea , Adulto , Feminino , Seguimentos , Humanos , Histerectomia , Estudos Longitudinais , Pessoa de Meia-Idade , Ovariectomia , Estudos Prospectivos , Fatores de Tempo
19.
Int J Gynaecol Obstet ; 75(3): 257-62, 2001 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-11728486

RESUMO

OBJECTIVE: The aim of this study was to evaluate the effect of tamoxifen on the endometrium of post-menopausal women with breast cancer and to examine the relationship between ultrasonography, hysteroscopy and histopathologic changes. METHOD: Included in this longitudinal study were 303 post-menopausal women taking 20 mg daily of tamoxifen. Hysteroscopy was performed in 83 patients with an endometrial thickness of only >or=5 mm and 34 with vaginal bleeding also. Forty-five asymptomatic patients (control group) underwent hysteroscopies. RESULT: The most frequent outcome in patients with endometrial thickness of only >or=5 mm was an atrophic endometrium in an empty cavity (79.5%) whereas simple hyperplasia (35.3%) was found in women with vaginal bleeding. Carcinoma was diagnosed in seven cases (5.9%). In the control group, no endometrial cancer was found. CONCLUSION: This study suggests that patients with a thickness >5 mm should be offered a whole hysteroscopic evaluation, whenever bleeding is reported.


Assuntos
Antineoplásicos Hormonais/efeitos adversos , Antineoplásicos Hormonais/uso terapêutico , Neoplasias da Mama/tratamento farmacológico , Neoplasias do Endométrio/patologia , Endométrio/efeitos dos fármacos , Endométrio/patologia , Mioma/patologia , Pós-Menopausa/efeitos dos fármacos , Tamoxifeno/efeitos adversos , Tamoxifeno/uso terapêutico , Idoso , Atrofia/induzido quimicamente , Atrofia/patologia , Hiperplasia Endometrial/induzido quimicamente , Hiperplasia Endometrial/patologia , Neoplasias do Endométrio/induzido quimicamente , Endométrio/diagnóstico por imagem , Feminino , Humanos , Histeroscopia , Estudos Longitudinais , Pessoa de Meia-Idade , Mioma/induzido quimicamente , Ultrassonografia
20.
Minerva Ginecol ; 51(11): 427-35, 1999 Nov.
Artigo em Italiano | MEDLINE | ID: mdl-10726442

RESUMO

BACKGROUND: Decision making about the opportunity of starting or continuing hormone replacement therapy (HRT) in menopause should rely on an overall evaluation of its risks and benefits for the women's health; the evaluation of HRT cost-benefit ratio, however, should include its possible outcomes from an economical point of view. In this view, and with the certainty that menopausal patients should be protected by proper treatments, our case series has been evaluated in order to improve the quality of our clinical schedules for both their access to HRT and the treatment follow-up. METHODS: Two groups of patients have been considered the first one consisted of 560 women observed during '97 for climacteric symptoms and candicated to begin HRT. The second one consisted of 100 women on HRT for 1 to 6 years. In the first group we considered which test and with which frequency were responsible for stopping or delay the beginning of therapy; while in the second group we evaluated the reasons for stopping treatment. RESULTS AND CONCLUSIONS: On the basis of our experience, the exams required before starting HRT seem to be the following: patient history, mammography, densitometry and endometrial sample as well as the parameters of glucose lipidic, coagulative and hepatic metabolism. Densitometry is useful in the annual follow-up only in patients with bone alterations from the beginning. The same exams seem required for the follow-up, with the exception of bone densitometry which should be performed yearly only in patients with bone demineralization.


Assuntos
Terapia de Reposição de Estrogênios , Menopausa/efeitos dos fármacos , Climatério/efeitos dos fármacos , Contraindicações , Terapia de Reposição de Estrogênios/efeitos adversos , Terapia de Reposição de Estrogênios/métodos , Terapia de Reposição de Estrogênios/estatística & dados numéricos , Feminino , Seguimentos , Humanos , Pessoa de Meia-Idade , Fatores de Tempo
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA